Leuven

• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• A clinical study of MK-2828 in healthy people (MK-2828-001) Ended
  2024-513377-51-00 1 2024-08-01 Atherosclerosis
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• In vivo PET of synaptic density in cognitive disorders: prospective evaluation of neuronal dysfunction and relation to symptomatology. Ended
  2024-514577-22-00 3 2024-07-12 Cognitive Disorders including Alzheimer's Disease, Frontotemporal deme
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec … Ended
  2023-505086-83-00 4 2024-07-10 Tourette Syndrome
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participant … Ended
  2024-512151-21-00 3 2024-06-19 Epilepsy
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Po … Ended
  2022-500410-26-01 4 2024-05-27 Cystic Fibrosis
• Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms. Ended
  2023-507781-13-00 1 2024-05-24 Patients with relapsed/refractory acute myeloid leukemia or myelodyspl
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• A Single-Ascending-Dose Study of MK6916 in Healthy Participants Ended
  2024-510971-39-00 1 2024-05-03 Acute and chronic Pain
• MK-2420 SAD Study Ended
  2024-511297-73-00 1 2024-05-03 Rheumatoid arthritis
• MK-4318 CIDF Target Engagement Study Ended
  2023-509645-12-00 3 2024-04-12 Pain
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended
  2023-504955-28-01 4 2024-03-14 Sleep disturbances associated with menopause
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Latera … Ended
  2023-506509-21-00 3 2024-03-08 Amyotrophic Lateral Sclerosis
• A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP). Ended
  2023-507311-35-00 9 2024-03-07 Erythropoietic Protoporphyria (EPP)
• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended
  2022-502453-33-00 4 2024-02-26 Advanced Endometrial Cancer
• A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM) Ended
  2022-502835-21-00 4 2024-02-23 cystic fibrosis bronchiectasis
• SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non- … Ended
  2022-500389-84-00 6 2024-02-16 Febrile neutropenia

Showing 913–936 of 1,135 trials